Evidence map›Paper›PMID 31356650›Full record

ArticlePLoS pathogens2019

Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection.

Xiaohua Ye, Xun Gui, Daniel C Freed, Zhiqiang Ku, Leike Li, Yuanzhi Chen, Wei Xiong, Xuejun Fan, Hang Su, Xi He and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cryptococcus neoformans, a global threat to human health.Infectious diseases of poverty · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Xiaohua YeTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.ORCID 0000-0002-2300-4739
Xun GuiTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Daniel C FreedMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.ORCID 0000-0002-9062-2713
Zhiqiang KuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Leike LiTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Yuanzhi ChenTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Wei XiongTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Xuejun FanTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Hang SuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Xi HeMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.
Richard R RustandiMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.
John W LoughneyMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.
Ningning MaWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
Amy S EspesethMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.
Jian LiuRutgers Medical School of New Jersey, Newark, NJ, United States of America.
Hua ZhuRutgers Medical School of New Jersey, Newark, NJ, United States of America.
Dai WangMRL, Merck & Co., Inc., Kenilworth, NJ, United States of America.
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.
Tong-Ming FuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.ORCID 0000-0003-1420-2271
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Texas, United States of America.ORCID 0000-0001-9309-2335
Brown Foundation · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USRutgers, The State University of New Jersey · USShenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that can cause disability in newborns and serious clinical diseases in immunocompromised patients. HCMV has a large genome with enormous coding potential; its viral particles are equipped with complicated glycoprotein complexes and can infect a wide range of human cells. Although multiple host cellular receptors interacting with viral glycoproteins have been reported, the mechanism of HCMV infection remains a mystery. Here we report identification of adipocyte plasma membrane-associated protein (APMAP) as a novel modulator active in the early stage of HCMV infection. APMAP is necessary for HCMV infection in both epithelial cells and fibroblasts; knockdown of APMAP expression significantly reduced HCMV infection of these cells. Interestingly, ectopic expression of human APMAP in cells refractory to HCMV infection, such as canine MDCK and murine NIH/3T3 cells, promoted HCMV infection. Furthermore, reduction in viral immediate early (IE) gene transcription at 6 h post infection and delayed nucleus translocation of tegument delivered pp65 at 4 h post infection were detected in APMAP-deficient cells but not in the wildtype cells. These results suggest that APMAP plays a role in the early stage of HCMV infection. Results from biochemical studies of APMAP and HCMV proteins suggest that APMAP could participate in HCMV infection through interaction with gH/gL containing glycoprotein complexes at low pH and mediate nucleus translocation of tegument pp65. Taken together, our results suggest that APMAP functions as a modulator promoting HCMV infection in multiple cell types and is an important player in the complex HCMV infection mechanism.

Indexed as

AdipocytesAnimalsCell MembraneCytomegalovirusCytomegalovirus InfectionsDogsEpithelial CellsFibroblastsGene Knockout TechniquesHost Microbial InteractionsHumansMadin Darby Canine Kidney CellsMembrane GlycoproteinsMiceNIH 3T3 CellsRecombinant ProteinsAPMAP protein, humanMembrane GlycoproteinsRecombinant ProteinsViral Structural Proteins

Identifiers

PMID31356650
PMCPMC6687193
OpenAlexW2966163075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.